345832 | Galectin-3C, Human, Recombinant, E. coli

345832
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      345832-100UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 100 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewRecombinant, human galectin-3 expressed in E. coli and subsequently cleaved with Clostridium histolyticum collagenase type VII to yield galectin-3C. The resulting galectin-3C is purified by affinity chromatography. Galectin-3C is a truncated form of galectin-3 that contains the carbohydrate binding domain but lacks the 107 amino acids at the N-terminus of galectin-3. It is suggested to play a key role in autoimmune diseases, allergic reactions, inflammation, tumor cell metastasis, atherosclerosis, and diabetes.
          Catalogue Number345832
          Brand Family Calbiochem®
          References
          ReferencesHoyer K.K., et al. 2004. Am. J. Pathol. 164, 893.
          John C.M., et al. 2003. Clin. Cancer Res. 9, 2374.
          Iurisci, I., et al. 2000. Clin Cancer Res 6, 1389.
          Van Den Brule, F. A., et al. 2000. Int. J. Cancer 89, 361.
          Inohara, H. 1999. Cancer 85, 2475.
          Nakamura, M., et al. 1999. Int. J. Oncol. 15, 143.
          Idikio, H., et al. 1998. Int. J. Oncol. 12, 1287.
          Ochieng, J., et al. 1998. Biochim. Biophys. Acta. 1379 97.
          Castronovo, V., et al. 1996. J. Pathol. 179, 43.
          Liu, F.T., et al. 1996. Biochemistry 35 6073.
          Schoeppner, H. L., et al. 1995. Cancer 75, 2818.
          Massa, S.M., et al. 1993. Biochemistry 32, 260.
          Oda, Y., et al. 1991. Gene 99, 279.
          Product Information
          FormLyophilized
          FormulationLyophilized from deionized water, 2µg lactose/µg lectin.
          Applications
          Biological Information
          Purity≥95% by SDS-PAGE
          Physicochemical Information
          ContaminantsEndotoxin: ≤ 1 EU/µg protein
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Blue Ice Only
          Toxicity Standard Handling
          Storage -20°C
          Avoid freeze/thaw Avoid freeze/thaw
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions (in the presence of a molar excess of lactose) are stable for up to 4 months at -20°C. For use in carbohydrate binding assays the solution should be dialyzed to remove the lactose stabilizer.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          345832

          References

          Reference overview
          Hoyer K.K., et al. 2004. Am. J. Pathol. 164, 893.
          John C.M., et al. 2003. Clin. Cancer Res. 9, 2374.
          Iurisci, I., et al. 2000. Clin Cancer Res 6, 1389.
          Van Den Brule, F. A., et al. 2000. Int. J. Cancer 89, 361.
          Inohara, H. 1999. Cancer 85, 2475.
          Nakamura, M., et al. 1999. Int. J. Oncol. 15, 143.
          Idikio, H., et al. 1998. Int. J. Oncol. 12, 1287.
          Ochieng, J., et al. 1998. Biochim. Biophys. Acta. 1379 97.
          Castronovo, V., et al. 1996. J. Pathol. 179, 43.
          Liu, F.T., et al. 1996. Biochemistry 35 6073.
          Schoeppner, H. L., et al. 1995. Cancer 75, 2818.
          Massa, S.M., et al. 1993. Biochemistry 32, 260.
          Oda, Y., et al. 1991. Gene 99, 279.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision30-June-2008 RFH
          DescriptionRecombinant, human galectin-3 expressed in E. coli and subsequently cleaved with Clostridium histiolyticum collagenase type VII to yield galectin-3C. The resulting galectin-3C is purified by affinity chromatography. Galectin-3C is a truncated form of galectin-3 that contains the carbohydrate binding domain but lacks the 107 amino acids at the N-terminus of galectin-3. It is suggested to play a key role in autoimmune diseases, allergic reactions, inflammation, tumor cell metastasis, atherosclerosis, and diabetes.
          FormLyophilized
          FormulationLyophilized from deionized water, 2µg lactose/µg lectin.
          Purity≥95% by SDS-PAGE
          ContaminantsEndotoxin: ≤ 1 EU/µg protein
          SolubilitySterile PBS (1 mg/ml)
          Storage -20°C
          Avoid freeze/thaw
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions (in the presence of a molar excess of lactose) are stable for up to 4 months at -20°C. For use in carbohydrate binding assays the solution should be dialyzed to remove the lactose stabilizer.
          Toxicity Standard Handling
          ReferencesHoyer K.K., et al. 2004. Am. J. Pathol. 164, 893.
          John C.M., et al. 2003. Clin. Cancer Res. 9, 2374.
          Iurisci, I., et al. 2000. Clin Cancer Res 6, 1389.
          Van Den Brule, F. A., et al. 2000. Int. J. Cancer 89, 361.
          Inohara, H. 1999. Cancer 85, 2475.
          Nakamura, M., et al. 1999. Int. J. Oncol. 15, 143.
          Idikio, H., et al. 1998. Int. J. Oncol. 12, 1287.
          Ochieng, J., et al. 1998. Biochim. Biophys. Acta. 1379 97.
          Castronovo, V., et al. 1996. J. Pathol. 179, 43.
          Liu, F.T., et al. 1996. Biochemistry 35 6073.
          Schoeppner, H. L., et al. 1995. Cancer 75, 2818.
          Massa, S.M., et al. 1993. Biochemistry 32, 260.
          Oda, Y., et al. 1991. Gene 99, 279.